Komori
Other Disclosures130AVeritas In Silico Inc.Pharmaceuticals

Notice of patent grant for a novel nucleic acid drug for the treatment of amyotrophic lateral sclerosis (ALS)

Patent rights have been granted in Japan for the substance patent covering the nucleic acid drug developed to treat ALS. The company will continue its research and explore clinical development in collaboration with development partners.

Worth reading
65In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Conditional
How definitive the wording is.

Announced details

Nucleic acid drug and its useTDP-43 MP13
Applicable field (uses covered by this announcement)

Treatment of amyotrophic lateral sclerosis (ALS)

What the company reported numerically
Usage history

Approx. 300,000 patients worldwide; approx. 10,000 patients in Japan

Relationship between the counterparty and the company
Veritas In Silico Inc.130A
Relationship with the Company

The parties have collaborated on the development of ALS treatments since 2017. They conducted joint research, and VIS acquired the rights to 2 nucleic acid drugs from The Jikei University School of Medicine, making VIS the patent applicant and rights holder. Both parties will bear their own research costs, and no payments or other transfers of value are planned.

CounterpartyThe Jikei University School of Medicine, Center for Integrated Medical Research, Department of Regenerative Medicine

Minato-ku, Tokyo. The Department of Regenerative Medicine is part of the Center for Integrated Medical Research, and its professor is Okano James Hirotaka (岡野ジェイムス洋尚). The department conducts ALS research and analyses using human iPSC models and pathological sections.

Registration number and expiry date

Application number: 特願2025-575964; international application number: PCT/JP2025/025230. Rights granted in Japan. Registration number and validity period: Not disclosed.

Impact on Business Performance

No change to the earnings forecast for the year ending December 2026. The development is expected to contribute to the enhancement of corporate value over the medium to long term.

The company does not address Contract Value / Offering price.

Source (materials cited by the company)

Paper published in the Journal of Cell Biology: “Dominant-negative isoform of TDP-43 is regulated by ALS-linked RNA-binding proteins”

Announced details
ItemDetails
Names of Products / Services CoveredNucleic acid drug and its use, TDP-43 MP13
CounterpartyThe Jikei University School of Medicine, Center for Integrated Medical Research, Department of Regenerative Medicine
Counterparty overviewMinato-ku, Tokyo. The Department of Regenerative Medicine is part of the Center for Integrated Medical Research, and its professor is Okano James Hirotaka (岡野ジェイムス洋尚). The department conducts ALS research and analyses using human iPSC models and pathological sections.
Relationship with the CompanyThe parties have collaborated on the development of ALS treatments since 2017. They conducted joint research, and VIS acquired the rights to 2 nucleic acid drugs from The Jikei University School of Medicine, making VIS the patent applicant and rights holder. Both parties will bear their own research costs, and no payments or other transfers of value are planned.
Applicable areaTreatment of amyotrophic lateral sclerosis (ALS)
Registration number and expiry dateApplication number: 特願2025-575964; international application number: PCT/JP2025/025230. Rights granted in Japan. Registration number and validity period: Not disclosed.
Usage historyApprox. 300,000 patients worldwide; approx. 10,000 patients in Japan
Impact on Business PerformanceNo change to the earnings forecast for the year ending December 2026. The development is expected to contribute to the enhancement of corporate value over the medium to long term.
SourcePaper published in the Journal of Cell Biology: “Dominant-negative isoform of TDP-43 is regulated by ALS-linked RNA-binding proteins”
Items this document does not state (9)
Contract ValueOffering priceContract DateLaunch dateAward/certification nameAwarding / certifying bodyLocationLocation scaleQuantitative Effects

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Because, following examination, patent rights for the substance patent were granted in Japan.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of patent grant for a novel nucleic acid drug for the treatment of amyotrophic lateral sclerosis (ALS) | Veritas In Silico Inc. (130A) timely disclosure | Komori